Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

The stock price of Vertex Pharmaceuticals has seen an 8.1% drop over the last five trading days, after the company announced that it will discontinue the clinical trials for VX-864, an experimental treatment for the rare genetic disorder alpha-1 antitrypsin. Note that earlier in October 2020.

What's Next For Vertex Pharmaceuticals Stock After An 8% Fall Last Week?

Shares of the biotech industry leader have taken a big hit thanks to a clinical development pipeline that hasn't produced any big wins lately.

Can Vertex Pharmaceuticals Recover From Its Latest Setback?

Smartsheet

Twilio

Vaxart

Zoom Video

PlayAGS

Air Products and Chemicals

Celsius Holdings

Nasdaq

With the trading day about halfway over, the markets were sliding lower to close out the week.

Nasdaq, Smartsheet, Twilio, Vaxart, Zoom Video and More Friday Afternoon Analyst Calls

Vertex Pharma (VRTX) stock is dropping on Friday following the release of results from a Phase 2 clinical trial for VX-864. The post VRTX Stock: The Disappointing News Sending Vertex Pharma Shares Lower appeared first on InvestorPlace.

VRTX Stock: The Disappointing News Sending Vertex Pharma Shares Lower

Analysts have provided the following ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 3 0 0 0 Somewhat Bullish 4 0 0 0 Indifferent 1 0 2 0 Somewhat Bearish 0 0 0 0 Bearish 0 0 0 0 In the last 3 months, 11 analysts have offered 12-month price targets for Vertex Pharmaceuticals. The company has an average price target of $258.91 with a high of $307.00 and a low of $205.00.

What 11 Analyst Ratings Have To Say About Vertex Pharmaceuticals

Vertex (VRTX) to discontinue further development of AATD candidate, VX-864, as it appears unlikely to benefit patients.

Vertex (VRTX) Ends Further Study on AAT Deficiency Candidate

CRISPR Therapeutics

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Crispr Therapeutics AG (NASDAQ: CRSP) have announced new data from Phase 1/2 clinical trials evaluating CTX001 in beta-thalassemia and sickle cell disease. Presenting data from two trials at the European Hematology Association annual meeting, the companies announced that three-month follow-up data of 22 patients with genetic blood disorders indicated a “consistent and sustained” response to the experimental drug CTX001.

Vertex, Crispr Unveil More Encouraging Data From Sickle Cell, Thalassemia Gene Therapy Trials

The shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) are down 11.7% at $191.50 at last check, after the company announced an experimental drug it was developing to treat a rare genetic condition did not translate into significant clinical benefits, and will therefore not advance into late-stage development.

VRTX Plummets After Ditching Experimental Drug

Another clinical setback isn't sitting well with shareholders today.

Why Vertex Pharmaceuticals Stock Is Getting Hammered Today

Shares of Vertex Pharmaceuticals Inc. tumbled 13.8% in premarket trading Friday, enough to pace the S&P 500's early decliners, after the biotechnology company released what was seen as disappointing data on its treatment for people with alpha-1 antitrypsin deficiency (AATD), which can lead to liver and lung disease. The stock was on track to open at the lowest price seen during regular-session hours since October 2019.

Vertex Pharmaceuticals stock tumbles to pace S&P 500 losers after disappointing drug trial data

It has a key advantage that should make a huge difference over the next 10 or more years.

Move Over, AMC and Dogecoin -- This Stock Could Be a Much Bigger Long-Term Winner

BOSTON & ZUG, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) and CRISPR Therapeutics (Nasdaq:CRSP) today announced new data on 22 patients, with follow-up of at least 3 months, and ranging from 4 months to 26 months, treated with the investigational CRISPR/Cas9-based gene-editing therapy, CTX001, that show a consistent and sustained response to treatment. CTX001 is being investigated in two ongoing Phase 1/2 clinical trials as a potential one-

Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that in a Phase 2 proof-of-concept study, VX-864 achieved rapid, consistent and statistically significant increases in mean functional alpha-1 antitrypsin (fAAT) levels of 2.2 to 2.3 micromolar from baseline in people with alpha-1 antitrypsin deficiency (AATD) with the PiZZ genotype, across three dose groups of VX-864 compared to placebo. VX-864 was generally well tolerated in the Phase 2 study. These da

Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency

The FDA approves Vertex's (VRTX) triple combination therapy, Trikafta, for treating cystic fibrosis in children aged between six to 11 years.

Vertex's (VRTX) Trikafta Gets FDA Nod for CF in Children

First Majestic Silver

Novavax

Unlike the "people's currency," these companies offer tangible growth that can make investors rich.

Ditch Dogecoin: These Stocks Are Screaming Buys in June

The Food and Drug Administration has expanded eligibility for Trikafta to include amenable cystic fibrosis patients aged 6 to 11.

Vertex Pharmaceuticals Nabs Key FDA Approval in Cystic Fibrosis

BOSTON--(BUSINESS WIRE)--Vertex today announced the U.S. FDA has approved TRIKAFTA for certain children with cystic fibrosis ages 6-11 years old.

CORRECTING and REPLACING Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations

The FDA has approved Vertex Pharmaceuticals Incorporated's (NASDAQ: VRTX) expanded use of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include children with cystic fibrosis (CF) ages 6 through 11 years. The approval covers children who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene responsive to Trikafta vitro data.

Vertex Pharma's Trikafta Triplet Therapy Wins FDA Approval For Expanded Use In Children 6-11 Years With Cystic Fibrosis

Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $209.16, marking a -0.37% move from the previous day.

Vertex Pharmaceuticals (VRTX) Dips More Than Broader Markets: What You Should Know

Yamana Gold

Broadcom

Value stocks have historically outperformed growth stocks during the early stages of an economic recovery.

3 Value Stocks That'll Make You Richer in June (and Beyond)

Biogen

SAGE Therapeutics

Binary events expected this month could have enormous implications for these drugmakers and their shareholders.

3 Biotech Stocks With Huge Catalysts in June

Vertex Pharmaceuticals has a lucrative suite of medicines for CF that will likely bring in approximately $6.8B in revenue in 2021. The early stage pipeline has multiple high risk, high reward programs.

Vertex Pharmaceuticals: An Undervalued Pipeline

Fate Therapeutics

Ionis Pharma

A modest amount goes a long way when you invest in biotech stocks.

The Best Biotech Stocks to Buy With $500

Vertex is an immensely profitable company thanks to its near-monopoly on treatments for Cystic Fibrosis. Its latest CF therapy, Trikafta, made $3.8bn sales in FY20, and $1.2bn in Q121 - FY21 total revenue forecast is for $6.8bn - up 10% year-on-year.

News for Vertex Pharmaceuticals Stock (VRTX)